<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: According to the current World Health Organization Classification of <z:e sem="disease" ids="C0598798" disease_type="Neoplastic Process" abbrv="">Lymphoid Tumours</z:e>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is subclassified into three grades according to the number of centroblasts </plain></SENT>
<SENT sid="1" pm="."><plain>Follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> grade 3 can be further divided into types A and B </plain></SENT>
<SENT sid="2" pm="."><plain>Almost <z:hpo ids='HP_0000001'>all</z:hpo> available genetic data on grade 3B follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> have been generated from <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with an additional diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> component </plain></SENT>
<SENT sid="3" pm="."><plain>The purely follicular type of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> grade 3B is a rare <z:hpo ids='HP_0002664'>neoplasm</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>DESIGN AND METHODS: We performed a detailed immunohistochemical (CD10, IRF4/MUM1, BCL2, Ig light chains) and genetic (translocations of BCL2, BCL6, MYC, IRF4) characterization of the largest series of purely follicular cases of grade 3B follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> available to date, comprising 23 tumor samples </plain></SENT>
<SENT sid="5" pm="."><plain>We also included 25 typical grade 1 or 2 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, 9 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with large centrocytes and/or high proliferation indices (FL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LCC</z:e>), 12 cases of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> grade 3A, 16 cases of diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> grade 3B and 15 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> in which a straightforward distinction between grades 3A and 3B was not possible </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Translocations affecting BCL2 and BCL6 genes are rare in grade 3B follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (2/23, 9% and 4/23, 17%) when compared with grade 1 or 2 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (22/25, 88%, P&lt;0.001 and 0/25, P&lt;0.05), FL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LCC</z:e> (7/9, 78%, P&lt;0.001 and 2/9, 22%), grade 3A follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (7/12, 58%, P&lt;0.01 and 2/12, 17%), unclassified grade 3 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (6/15, 40% and 2/15, 13%) and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> grade 3B (2/16, 13% and 8/16, 50%, P&lt;0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>MYC translocations were detected occasionally in FL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LCC</z:e>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> grade 3B, and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> grade 3B (13%-22%), but not in grade 1, 2 or 3A follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (P&lt;0.05 when compared with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> grade 3B) </plain></SENT>
<SENT sid="8" pm="."><plain>Both follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> grade 3B and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> grade 3B were enriched in samples with a CD10(-)IRF4/MUM1(+) immunophenotype (8/19, 42% and 7/16, 44%), with the vast majority of them lacking BCL2 translocations </plain></SENT>
<SENT sid="9" pm="."><plain>In contrast, 42/46 grade 1 or 2 follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, FL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LCC</z:e> and grade 3A follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were CD10(+) (91%) while 0/46 expressed IRF4/MUM1 </plain></SENT>
<SENT sid="10" pm="."><plain>None of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples tested with increased IRF4/MUM1-expression harbored a translocation of the IRF4 gene locus </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Our results show that grade 3B follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> form a distinct category of follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with infrequent BCL2 and BCL6 translocations, while grades 1, 2 and 3A follicular <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and FL/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">LCC</z:e> display homogeneous features with frequent BCL2 translocations and a CD10(+)IRF4/MUM1(-) immunophenotype </plain></SENT>
</text></document>